- Home
- APVO vs ATXG Comparison
APVO vs ATXG Comparison
Compare APVO & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- ATXG
- Stock Information
- Founded
- APVO 2016
- ATXG 2014
- Country
- APVO United States
- ATXG China
- Employees
- APVO N/A
- ATXG N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- ATXG Professional Services
- Sector
- APVO Health Care
- ATXG Consumer Discretionary
- Exchange
- APVO Nasdaq
- ATXG Nasdaq
- Market Cap
- APVO 4.1M
- ATXG 3.8M
- IPO Year
- APVO N/A
- ATXG N/A
- Fundamental
- Price
- APVO $3.06
- ATXG $0.60
- Analyst Decision
- APVO Strong Buy
- ATXG
- Analyst Count
- APVO 1
- ATXG 0
- Target Price
- APVO $5,920.00
- ATXG N/A
- AVG Volume (30 Days)
- APVO 191.0K
- ATXG 2.4M
- Earning Date
- APVO 08-07-2025
- ATXG 08-13-2025
- Dividend Yield
- APVO N/A
- ATXG N/A
- EPS Growth
- APVO N/A
- ATXG N/A
- EPS
- APVO N/A
- ATXG N/A
- Revenue
- APVO N/A
- ATXG $4,180,913.00
- Revenue This Year
- APVO N/A
- ATXG N/A
- Revenue Next Year
- APVO N/A
- ATXG N/A
- P/E Ratio
- APVO N/A
- ATXG N/A
- Revenue Growth
- APVO N/A
- ATXG N/A
- 52 Week Low
- APVO $2.81
- ATXG $0.49
- 52 Week High
- APVO $381.10
- ATXG $1.86
- Technical
- Relative Strength Index (RSI)
- APVO 38.28
- ATXG 42.51
- Support Level
- APVO $3.01
- ATXG $0.62
- Resistance Level
- APVO $3.18
- ATXG $0.75
- Average True Range (ATR)
- APVO 0.16
- ATXG 0.06
- MACD
- APVO 0.19
- ATXG -0.00
- Stochastic Oscillator
- APVO 45.45
- ATXG 21.11
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.